Form 4: ATAI Life Sciences N.V.: Chief Medical Officer Granted Stock Options

Kevin James Craig, Chief Medical Officer of ATAI Life Sciences N.V., was granted stock options for 757,915 common shares on March 3, 2025.

Summary

• Kevin James Craig, the Chief Medical Officer of ATAI Life Sciences N.V., was granted stock options on March 3, 2025.
• The stock options are for 757,915 common shares with an exercise price of $1.50.
• The options vest as to 25% on January 1, 2026, and the remaining shares vest in 36 equal monthly installments thereafter.
• The options expire on March 3, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management interests with shareholders. The sentiment is neutral to slightly positive.

Positives

• The grant of stock options to the Chief Medical Officer aligns his interests with those of the shareholders.
• The vesting schedule incentivizes long-term commitment and performance.

Industry Context

Stock option grants are a common practice in the biotech industry to incentivize key executives and align their interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotechnology industry.
• The size of the grant and the vesting schedule are typical for a Chief Medical Officer role in a company of ATAI Life Sciences' size and stage of development.
• Comparisons can be made to similar grants at companies like Compass Pathways or MindMed, considering factors like market capitalization and executive responsibilities.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the Chief Medical Officer to drive company success.
• Employees may see the grant as a sign of confidence in the company's future.

Key Dates